Tweet
New studies have been hammering this supplement. The $30 billion industry is nonplussed with research that shows no benefit, cardiovascularly or in MS. You are far better off just eating fish.
https://www.theguardian.com/lifeands...udy-no-benefit
-----------------
And here's a recent study that is MS specific....
Evaluating the effect of adding Fish oil to Fingolimod on TNF-α, IL1β, IL6, and IFN-γ in patients with relapsing-remitting multiple sclerosis: A double-blind randomized placebo-controlled trial
https://doi.org/10.1016/j.clineuro.2017.10.004
Highlights
•Administration of fish oil has no effect on decreasing TNF-α, IFN-γ, IL6, and IL-1β in MS patients.
•Administration of low dose fish oil does not improve disability in MS patients.
•Fish oil seems not to be an effective add-on therapy for multiple sclerosis.
Abstract
Objectives
Fish oil is claimed to improve outcome in multiple sclerosis (MS) through anti-inflammatory and antioxidant effects by reducing cytokines including TNF-α, IFN-γ, IL6, and IL-1β. We aimed to evaluate the efficacy of adding fish oil to Fingolimod on these serum cytokines.
Patients and methods
This double-blind randomized trial was conducted during April 2015 to September 2016 in Isfahan, Iran. Patients with diagnosis of relapsing remitting MS, aged 18–45 years old and expanded disability status scale (EDSS) ≤5 were enrolled in the study. The experimental group received 1 g/day of fish oil. Serum levels of TNF-α, IFN-γ, IL6, and IL-1β were measured before intervention, 6 months, and 12 months after intervention as the primary outcome. Also, EDSS was evaluated before and at the end of study.
Results
50 patients were recruited initially and nine of them left the study. We found no difference between serum levels of TNF-α, IFN-γ, IL6, and IL-1β at three time-points between two groups (P-value >0.05). Also, there was no statistically significant difference in the mean EDSS between the experimental group and the control group after 12 months of intervention (P-value = 0.08).
Conclusions
Administration of fish oil did not lower the serum levels of TNF-α, IL1β, IL6, and IFN-γ compared to placebo. Similarly, it did not improve the disability in patients.
-----------------
And the American Academy of Neurology earlier released this back in 2014....
Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis
Report of the Guideline Development Subcommittee of the American Academy of Neurology
Vijayshree Yadav, Christopher Bever, James Bowen, Allen Bowling, Bianca Weinstock-Guttman, Michelle Cameron, Dennis Bourdette, Gary S. Gronseth, Pushpa Narayanaswami
First published March 24, 2014
https://doi.org/10.1212/WNL.0000000000000250
Abstract
Objective: To develop evidence-based recommendations for complementary and alternative medicine (CAM) in multiple sclerosis (MS).
Methods: We searched the literature (1970–March 2011; March 2011−September 2013 MEDLINE search), classified articles, and linked recommendations to evidence.
Results and recommendations: Clinicians might offer oral cannabis extract for spasticity symptoms and pain (excluding central neuropathic pain) (Level A). Clinicians might offer tetrahydrocannabinol for spasticity symptoms and pain (excluding central neuropathic pain) (Level B). Clinicians should counsel patients that these agents are probably ineffective for objective spasticity (short-term)/tremor (Level B) and possibly effective for spasticity and pain (long-term) (Level C). Clinicians might offer Sativex oromucosal cannabinoid spray (nabiximols) for spasticity symptoms, pain, and urinary frequency (Level B). Clinicians should counsel patients that these agents are probably ineffective for objective spasticity/urinary incontinence (Level B). Clinicians might choose not to offer these agents for tremor (Level C). Clinicians might counsel patients that magnetic therapy is probably effective for fatigue and probably ineffective for depression (Level B); fish oil is probably ineffective for relapses, disability, fatigue, MRI lesions, and quality of life (QOL) (Level B); ginkgo biloba is ineffective for cognition (Level A) and possibly effective for fatigue (Level C); reflexology is possibly effective for paresthesia (Level C); Cari Loder regimen is possibly ineffective for disability, symptoms, depression, and fatigue (Level C); and bee sting therapy is possibly ineffective for relapses, disability, fatigue, lesion burden/volume, and health-related QOL (Level C). Cannabinoids may cause adverse effects. Clinicians should exercise caution regarding standardized vs nonstandardized cannabis extracts and overall CAM quality control/nonregulation. Safety/efficacy of other CAM/CAM interaction with MS disease-modifying therapies is unknown.
GLOSSARY
AAN=American Academy of Neurology; AE=adverse effect; CAM=complementary and alternative medicine; CBD=cannabidiol; CI=confidence interval; DSM-IV=Diagnostic and Statistical Manual of Mental Disorders, 4th edition; EDSS=Expanded Disability Status Scale; FDA=US Food and Drug Administration; FSS=Fatigue Severity Scale; GB=ginkgo biloba; GNDS=Guy's Neurological Disability Scale; HRQOL=health-related QOL; MFIS=Modified Fatigue Impact Scale; MS=multiple sclerosis; MSIS=Multiple Sclerosis Impact Scale; OCE=oral cannabis extract; PPMS=primary progressive MS; QOL=quality of life; RCT=randomized controlled trial; RRMS=relapsing-remitting MS; SAE=serious adverse effect; SPMS=secondary progressive MS; THC=tetrahydrocannabinol; VAS=visual analog scale
Approved by the Guideline Development Subcommittee on January 12, 2013; by the Practice Committee on March 13, 2013; and by the AANI Board of Directors on December 11, 2013.
https://www.theguardian.com/lifeands...udy-no-benefit
-----------------
And here's a recent study that is MS specific....
Evaluating the effect of adding Fish oil to Fingolimod on TNF-α, IL1β, IL6, and IFN-γ in patients with relapsing-remitting multiple sclerosis: A double-blind randomized placebo-controlled trial
https://doi.org/10.1016/j.clineuro.2017.10.004
Highlights
•Administration of fish oil has no effect on decreasing TNF-α, IFN-γ, IL6, and IL-1β in MS patients.
•Administration of low dose fish oil does not improve disability in MS patients.
•Fish oil seems not to be an effective add-on therapy for multiple sclerosis.
Abstract
Objectives
Fish oil is claimed to improve outcome in multiple sclerosis (MS) through anti-inflammatory and antioxidant effects by reducing cytokines including TNF-α, IFN-γ, IL6, and IL-1β. We aimed to evaluate the efficacy of adding fish oil to Fingolimod on these serum cytokines.
Patients and methods
This double-blind randomized trial was conducted during April 2015 to September 2016 in Isfahan, Iran. Patients with diagnosis of relapsing remitting MS, aged 18–45 years old and expanded disability status scale (EDSS) ≤5 were enrolled in the study. The experimental group received 1 g/day of fish oil. Serum levels of TNF-α, IFN-γ, IL6, and IL-1β were measured before intervention, 6 months, and 12 months after intervention as the primary outcome. Also, EDSS was evaluated before and at the end of study.
Results
50 patients were recruited initially and nine of them left the study. We found no difference between serum levels of TNF-α, IFN-γ, IL6, and IL-1β at three time-points between two groups (P-value >0.05). Also, there was no statistically significant difference in the mean EDSS between the experimental group and the control group after 12 months of intervention (P-value = 0.08).
Conclusions
Administration of fish oil did not lower the serum levels of TNF-α, IL1β, IL6, and IFN-γ compared to placebo. Similarly, it did not improve the disability in patients.
-----------------
And the American Academy of Neurology earlier released this back in 2014....
Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis
Report of the Guideline Development Subcommittee of the American Academy of Neurology
Vijayshree Yadav, Christopher Bever, James Bowen, Allen Bowling, Bianca Weinstock-Guttman, Michelle Cameron, Dennis Bourdette, Gary S. Gronseth, Pushpa Narayanaswami
First published March 24, 2014
https://doi.org/10.1212/WNL.0000000000000250
Abstract
Objective: To develop evidence-based recommendations for complementary and alternative medicine (CAM) in multiple sclerosis (MS).
Methods: We searched the literature (1970–March 2011; March 2011−September 2013 MEDLINE search), classified articles, and linked recommendations to evidence.
Results and recommendations: Clinicians might offer oral cannabis extract for spasticity symptoms and pain (excluding central neuropathic pain) (Level A). Clinicians might offer tetrahydrocannabinol for spasticity symptoms and pain (excluding central neuropathic pain) (Level B). Clinicians should counsel patients that these agents are probably ineffective for objective spasticity (short-term)/tremor (Level B) and possibly effective for spasticity and pain (long-term) (Level C). Clinicians might offer Sativex oromucosal cannabinoid spray (nabiximols) for spasticity symptoms, pain, and urinary frequency (Level B). Clinicians should counsel patients that these agents are probably ineffective for objective spasticity/urinary incontinence (Level B). Clinicians might choose not to offer these agents for tremor (Level C). Clinicians might counsel patients that magnetic therapy is probably effective for fatigue and probably ineffective for depression (Level B); fish oil is probably ineffective for relapses, disability, fatigue, MRI lesions, and quality of life (QOL) (Level B); ginkgo biloba is ineffective for cognition (Level A) and possibly effective for fatigue (Level C); reflexology is possibly effective for paresthesia (Level C); Cari Loder regimen is possibly ineffective for disability, symptoms, depression, and fatigue (Level C); and bee sting therapy is possibly ineffective for relapses, disability, fatigue, lesion burden/volume, and health-related QOL (Level C). Cannabinoids may cause adverse effects. Clinicians should exercise caution regarding standardized vs nonstandardized cannabis extracts and overall CAM quality control/nonregulation. Safety/efficacy of other CAM/CAM interaction with MS disease-modifying therapies is unknown.
GLOSSARY
AAN=American Academy of Neurology; AE=adverse effect; CAM=complementary and alternative medicine; CBD=cannabidiol; CI=confidence interval; DSM-IV=Diagnostic and Statistical Manual of Mental Disorders, 4th edition; EDSS=Expanded Disability Status Scale; FDA=US Food and Drug Administration; FSS=Fatigue Severity Scale; GB=ginkgo biloba; GNDS=Guy's Neurological Disability Scale; HRQOL=health-related QOL; MFIS=Modified Fatigue Impact Scale; MS=multiple sclerosis; MSIS=Multiple Sclerosis Impact Scale; OCE=oral cannabis extract; PPMS=primary progressive MS; QOL=quality of life; RCT=randomized controlled trial; RRMS=relapsing-remitting MS; SAE=serious adverse effect; SPMS=secondary progressive MS; THC=tetrahydrocannabinol; VAS=visual analog scale
Approved by the Guideline Development Subcommittee on January 12, 2013; by the Practice Committee on March 13, 2013; and by the AANI Board of Directors on December 11, 2013.